Technology | Angiography | March 15, 2017

FDA Clears Artis Pheno Angiography System from Siemens Healthineers

Robotic system helps hospitals combat infection, facilitates complex procedures

Siemens Healthineers, Artis pheno angiography system, FDA approval, ACC 2017, RSNA 2017

March 15, 2017 — The U.S. Food and Drug Administration (FDA) has cleared the Artis pheno robotic C-arm angiography system from Siemens Healthineers created for use in minimally invasive interventional procedures.

The Artis pheno possesses not only a zen40HDR flat panel detector and GIGALIX X-ray tube for high image quality, but also new 2k recording technology capable of delivering 2-D imaging resolution four times higher in all recording processes than its predecessor system, the Artis Zeego. 

Siemens Healthineers designed the Artis pheno in part to assist hospitals in combating high rates of patient infection. An antimicrobial coating on the surface of the C-arm, stand and patient table may help prevent bacteria and viruses from multiplying on the system. The hermetically sealed housing of the C-arm and table modules, as well as easy-to-access spaces, aid in system cleaning. Additionally, the Artis pheno’s cabling is routed inside the system to prevent cables from becoming dirty and potentially transmitting bacteria. And since it is mounted on the floor rather than the ceiling, the system is not only easier to install in the operating suite, but the sterile air flow from the ceiling is uninterrupted.

The StructureScout exposure control feature can regulate acquisition parameters to automatically achieve optimal image contrast at ALARA (As Low As Reasonably Achievable) dose levels. And because the system also can scan up to 68 percent faster than its predecessor, its syngo DynaCT clinical software application can produce 3-D images that use less contrast media, increasing patient safety by decreasing the load on the kidneys.

The Artis pheno has a free inner diameter of 37.6 inches, which provides staff with enough room to remain at the side of pediatric patients. Bariatric patients are supported by the multi-tilt table, which can accommodate up to 617 pounds. And like the Artis zeego, the Artis pheno’s robotic construction provides a flexible isocenter, so it can follow all table positions while representing the patient’s target area from virtually any angle.

Interventionalists not only need to work easily while standing so they can perform lengthy procedures without fatigue, but they also must maintain optimal access within the operating area. Addressing these needs, the easy-float tabletop of the Artis pheno multi-tilt table can be moved with minimal effort, regardless of the tabletop’s angle or the patient‘s weight. The system recognizes the tabletop’s position at all times and automatically aligns to it. The memory positions allow the user to move the C-arm out of the operating area quickly and back to the same position for further imaging, so the user can perform a quality check during the operation.

The Artis pheno angiography system includes a broad array of software applications to aid users in performing a variety of interventional procedures

  • CLEARstent Live offers real-time verification of stent positioning during implantation;
  • syngo CTO Guidance enables better clinician planning by delivering automatic segmentation of coronary computed tomography angiograms (cCTAs) as well as providing procedural guidance to avoid foreshortening;
  • syngo DynaCT Cardiac permits 3-D visualization of a patient’s beating heart;
  • syngo Aortic Valve Guidance delivers fast, precise 3-D information on aortic root anatomy for transcatheter aortic valve replacement (TAVR) procedures; and
  • The syngo Fusion package superimposes previously obtained CT, magnetic resonance (MR) or positron emission tomography (PET)/CT images onto live fluoroscopy images.

For more information: www.usa.healthcare.siemens.com

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init